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Background: This study compared the methodological requirements for early health technology appraisal (HTA) by
the Federal Joint Committee/Institute for Quality and Efficiency in Health Care (G-BA/IQWiG; Germany) and the
National Institute for Health and Care Excellence (NICE; England).
Methods: The following aspects were examined: guidance texts on methodology and information sources for the
assessment; clinical study design and methodology; statistical analysis, quality of evidence base, extrapolation of
results (modeling), and generalisability of study results; and categorisation of outcome.
Results: There is some degree of similarity regarding basic methodological elements such as selection of
information sources (e.g. preference of randomised controlled studies, RCTs) and quality assessment of the available
evidence. Generally, the approach taken by NICE seems to be more open and less restrictive as compared with
G-BA/IQWiG. Any kind of potentially relevant evidence is requested, including data from non-RCTs. Surrogate
endpoints are also accepted more readily, if they are reasonably likely to predict clinical benefit. Modeling is
expected to be performed wherever possible and appropriate, e.g. for study duration, patient population, choice of
comparator, and type of outcomes. The resulting uncertainty is quantified through sensitivity analyses before
making a recommendation regarding reimbursement. By contrast, G-BA/IQWiG bases its assessment and quantification
of the additional benefit largely, if not exclusively, on evidence of the highest level and quality and on measurements
of “hard” clinical endpoints. This more conservative approach rather firmly dismisses evidence from non-RCTs and
measurements of surrogate endpoints that have not or only partly been validated. Moreover, neither qualitative
extrapolation nor quantitative modeling of data is done.
Conclusions: Methodological requirements differed mainly in the acceptance of low-level evidence, surrogate
endpoints, and data modeling. Some of the discrepancies may be explained, at least in part, by differences in the
health care system and procedural aspects (e.g. timing of assessment).
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In most Western countries, a comparative analysis of cli-
nical efficacy and/or effectiveness is performed to sup-
port national decisions regarding reimbursement or
pricing of a pharmaceutical drug or other health care
technology. Benefit evaluations can be divided into rapid
(or early) assessments for single new pharmaceuticals
and full assessments for (all) available therapeutic op-
tions. For rapid assessments, which are usually per-
formed soon after marketing authorisation, a timeframe
is often pre-specified, e.g. 6 months for early benefitCorrespondence: victor.ivandic@promed-writing.com
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in any medium, provided the original work is passessments in Germany and approx. 39 weeks for rapid
health technology appraisal (HTA) in England. For full
(non-rapid) assessments, which are often conducted
when the pharmaceutical has already been available on
the market for several years, there is usually no fixed
timeframe (in England, full assessments are subject to a
specific timeframe, approx. 54 weeks).
The conditions for acceptance of evidence for clinical
benefit vary among national HTA agencies since the struc-
ture of the health care systems differs greatly from country
to country. While the healthcare system in England, for
example, is a primarily tax-based national health service,
an insurance-based health system is in place in Germanyen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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pany profit rather than drug prices are subject to direct
regulation, at present. Until end of 2010, drug prices in
Germany were not regulated but were indirectly in-
fluenced by the reimbursement system (e.g. fixed pricing,
agreements on discounts).
Since 1 January 2011 all new patent-protected phar-
maceuticals undergo a systematic assessment of the
additional benefit upon market entry in Germany. The
purpose of the rapid benefit assessment pursuant to § 35a
Social Code Book V (SGB V) [3] is primarily to support
pricing decisions according to § 130b SGB V. The overall
aim of the new legislation is to counteract the dispropor-
tional increase in costs for pharmaceuticals that are not
yet regulated by the fixed pricing system. At the same
time, the availability of innovative pharmaceuticals to the
patients is to be maintained at adequate costs for the
health care system.
There are two HTA organisations that give input for re-
imbursement decisions of pharmaceuticals in Germany.
The Institute for Quality and Efficiency in Health Care
(IQWiG) usually carries out the benefit assessment and
prepares a recommendation with a quantification of the
additional benefit. The Federal Joint Committee (G-BA)
makes the final decision regarding the benefit assessment.
Subsequently, pharmaceutical company and Central Federal
Association of the Statutory Health Insurance (GKV-SpV)
agree on a reimbursement price (if fixed pricing is not
possible), which takes into account the costs of the com-
parator therapy and the additional benefit of the new drug.
If price negotiations fail, the price is set by a board of arbi-
tration (Figure 1). A major difference between Germany
and England is that in Germany drugs are reimbursedFigure 1 Early benefit assessment in Germany according to § 35a SG
for Pharmaceuticals; G-BA = Federal Joint Committee; GKV-SpV = Central Fede
for Quality and Efficiency in Health Care; N = No; SGB V = Social Code Book V;
assessment period; 3) with retroactive effect from end of 12-month assessme
5) according to § 35b SGB V, if arbitrament is not accepted.immediately after regulatory approval (Figure 1) and irre-
spective of the outcome of the early benefit assessment
while in England reimbursement depends on the outcome
of the early assessment (“fourth hurdle”).
The aim of the comparative benefit analysis in England
is to provide input for national reimbursement decisions
by the National Health Service (NHS). The technology
appraisals are performed by the National Institute for
Health and Care Excellence (NICE). As stipulated in the
Directions of the Secretary of State [4], the purpose of
the appraisal by NICE is to assess the clinical benefits and
the costs of interventions and to make recommendations
as to “whether, on balance, the intervention can be re-
commended as a cost-effective use of NHS resources in
general, or for specific indications, or for defined sub-
groups of patients” [5]. Thus, clinical effectiveness and
cost-effectiveness of a technology are examined in one
and the same appraisal.
The outcome of HTA for a new medical technology in
England is issued early, in form of guidance by NICE,
and may thus be considered by HTA authorities in other
EU countries. At the same time, England represents a
major market within the EU for the pharmaceutical in-
dustry [6]. Therefore, in this study, the requirements for
demonstrating the benefit of a drug in Germany were
compared with those in England. The aim was to ex-
plore to which extent the requirements differ, a question
of relevance e.g. to a pharmaceutical company wishing
to submit a dossier for HTA in both countries. The fin-
dings are presented separately for the two HTA systems
and thus may serve as stand-alone references. A concise,
integrated comparison follows to highlight the main simi-
larities and differences in the methodological requirements.B V (AMNOG). Abbr.: AMNOG = German Law for Reforming the Market
ral Association of the Statutory Health Insurance Funds; IQWiG = Institute
Y = Yes. 1) effective for up to 1 year; 2) effective from end of 12-month
nt period; 4) if deemed required due to insufficient evidence base;
Figure 2 Hierarchy of legal texts related to early benefit
assessment in Germany. Abbr. AMNOG = Arzneimittelmarkt-
Neuordnungsgesetz (German Law for Reforming the Market for
Pharmaceuticals).
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explored.
Methods
An overview is primarily given of the methodological
requirements currently used for the relative effectiveness
assessment by NICE in England and the early benefit
assessment by G-BA/IQWiG in German. To allow com-
parison between early benefit assessment in Germany and
single technology appraisal in England, the following as-
pects were examined: guidance texts on methodology and
information sources for the assessment (e.g. dossier); cli-
nical study design and methodology (e.g. study type and
duration, comparator, endpoints); statistical analysis (e.g.
systematic reviews, meta-analyses, sensitivity analyses),
quality of evidence base, extrapolation of results (mode-
ling), and generalisability of study results (i.e. external
validity); and categorisation of outcome. The cut-off date
for information considered for inclusion in the manuscript
is 31 August 2013.
This study focused on the comparative evaluation of
clinical effectiveness, which is always performed in both
legal systems directly after market access (“early assess-
ment”). The area of cost-effectiveness assessment, however,
was not subject of this study as it does not form part of the
initial, early benefit assessment in Germany. This step may
be performed at a later stage under specific circumstances,
e.g. if the parties have not come to an agreement during
the regular price negotiation (Figure 1). By contrast, cost-
effectiveness is always evaluated in England due to the
nature and purpose of the appraisal; criteria for assess-
ments include direct and indirect costs, e.g. social produc-
tivity; resource management; resource use identification,
measurement, and costing; discounting; equity; and impact
on NHS budget and services [5]. Regulatory and process-
related aspects are presented where necessary, i.e. if rele-
vant in the context of the evaluation or associated with
methodological requirements. A detailed comparison of
the legal or procedural elements is outside of the scope
of the present review. Finally, the study is restricted to
pharmaceutical drugs since the benefit assessment in
Germany according to AMNOG does not apply to all types
of health technologies.
Results
Methodological requirements for early benefit
assessment in Germany (G-BA/IQWiG)
Legal basis, guidance texts, and information sources
Regulatory and guidance texts relevant to early benefit
assessment The hierarchy of legal texts related to (cost-)
benefit assessment is shown in Figure 2. The SGB V [3]
is the legal basis of the statutory health insurance funds
(GKV) in Germany. The German law for reforming themarket for pharmaceuticals (AMNOG) introduced an
entirely new means of price regulation for recently
authorised pharmaceuticals by establishing a new § 35a
SGB V on the “Assessment of benefit for pharma-
ceuticals with new active substances”. This early benefit
assessment is mandatory for all new pharmaceuticals or
new therapeutic indications authorised in Germany and
is based on information provided by the pharmaceutical
company (in form of a dossier).
The benefit assessment is described in greater detail in
the German Ordinance for Assessing the Benefits of Phar-
maceuticals (AM-NutzenV) [7]. This regulation entered
into force as from 1 January 2011 - like the AMNOG -
and provided the basis for the new supplement of G-BA’s
Rules of Procedure.
The Rules of Procedure of G-BA (G-BA VerfO) are
important as they specify the methodological basis for
decision-making in many areas. In a resolution, which
entered into force on 22 January 2011, G-BA added an
additional chapter to its rules of procedure, which is
entitled “Chapter 5: Assessment of the benefits of phar-
maceuticals according to § 35a SGB V”. This supplement
completes the AMNOG and related legal regulations by
joining the regulations in an integrative set of rules. In
Annex II of the Supplement of the G-BA VerfO (Suppl.
G-BA VerfO) [8], the specifications on the format and
structure of the dossiers and documents to be submitted
are described in detail, and comprehensive guidance on
the methodological requirements is given.
The methodology used for benefit assessment by IQWiG
is described in form of a methods paper called “General
Methods 4.0” (IQWiG GM 4.0), which is available publicly
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methodology is very high.
Information sources For an early benefit assessment
according to § 35a SGB V, the main source is a dossier
that is provided by the drug manufacturer. The structure
and format of the dossier (Figure 3), the documents to
be submitted and technical standards are pre-specified;
mandatory and optional contents are described, exam-
ples and explanations are given, and placeholders are
provided for text entries and tables to be filled with data.
Finally, a check list is offered to test for formal com-
pleteness of the dossier. The size of the dossier (main
body), which is written in German, usually exceeds 300
pages, and the volume of appendices is in the range of
1000s of pages.
For the first assessment, at time of marketing, the li-
censing studies form the basis of information in the dos-
sier. In addition, a systematic literature search is always
required (Section 4.2.3.2 Suppl. G-BA VerfO).
A literature search should be performed using the
MEDLINE, EMBASE, and Cochrane databases as a
minimum. Further details regarding the search strategies
(e.g. cut-off date, block-wise search, or separate searches
by indication, intervention and study type) are provided
in Section 4.2.3.2 Suppl. G-BA VerfO. In any case, the
process is to be documented, and deviations from the
recommendations are to be justified.
The methodology used for systematic literature search
should be suitable for identifying both published and un-
published studies (Section 4.2.3 Suppl. G-BA VerfO). To
ensure that all on-going, prematurely discontinued and
completed studies from third-party sponsors are identi-
fied, web-based study registries are always to be searched
(Section 4.2.3.3 Suppl. G-BA VerfO).Figure 3 Structure of the dossier for early benefit assessment
in Germany.Confidential data submitted in Module 5 of the dossier
may also be part of the assessment. While content of
Module 5 might be labeled as confidential, all information
and data used in the assessment has to be part of Modules
1 to 4 and thus must be publicly available. Otherwise,
proof of additional benefit is not considered to have been
provided due to an incomplete dossier (§9 par. 3 G-BA
VerfO; § 35a par. 1 SGB V).
During the dossier review by IQWiG, input from exter-
nal medical experts and patients or patient organisation is
sought through questionnaires (and by discussion) [10].
Furthermore, pharmaceutical companies, industry organi-
sations, pharmacists’ associations, umbrella organisations
of medical professionals, and scientific experts are given
the opportunity (for 3 weeks) to make written comments
on the assessment report, which is prepared by IQWiG
and published by G-BA (§ 19 par. 1 s. 1 G-BA VerfO).
Additionally, verbal hearings may be conducted after the
written hearing procedure and before a final decision is
made by G-BA (§ 35a par. 3 s. 2 SGB V in connection with
§ 19 par. 1 s. 2 G-BAVerfO).
As per § 5 par. 5 s. 2 AM-NutzenV, the available evi-
dence is the basis for decision-making. Due to the early
time point of benefit assessment, the evidence base may
be limited. If the evidence provided is not deemed suffi-
cient, e.g. because of poor result certainty or doubts re-
garding the safety or appropriateness, G-BA can demand
additional evidence as part of its decision (§ 35b par. 2
SGB V). A deadline, by when these data should be pro-
vided (e.g. at the latest after 3 years) and the type of study
design (e.g. pragmatic randomised controlled trials) are
predetermined by G-BA (§ 92 par. 2a SGB V). The health
care provision studies should preferably be conducted in
Germany to ascertain that results are applicable to the
local health care conditions.
Clinical study design and methodology
Study design features The study design and methods of
the included studies are to be described to ensure that the
dossier contains all information relevant for benefit assess-
ment (Section 4.2.5.1 Suppl. G-BA VerfO; Section 7.1.4
IQWiG GM 4.0). The requirements should at least comply
with the established international standards for rando-
mised studies (CONSORT) [11], non-randomised inter-
ventional studies (TREND-2) [12], and epidemiological
observational studies (STROBE) [13]. The importance of
study design aspects in benefit assessment (e.g. compliance
to good clinical practice (GCP), sample size calculation,
control group, blinding, randomisation, interim analyses,
prospective and retrospective designs) is discussed in detail
in Section 7.1.2 and 7.1.4 of the IQWiG GM 4.0.
Randomised clinical trials (RCTs) and, in particular,
direct comparison trials are preferred to protect against
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domisation [14]. If it is not possible or inadequate to pro-
vide or generate best-level evidence, the pharmaceutical
company may also submit best-available evidence, justi-
fying its suitability for the benefit assessment (§ 5 par. 3
and 6 AM-NutzenV; § 5 par. 3 G-BA VerfO; Section 4.5.2
and 4.5.3 Suppl. G-BAVerfO). Finally, IQWiG may accept
results from well documented case series, which have a
lower validity, if the intervention brings about a “dramatic
effect”, e.g. life-saving substitution of essential hormones
(Section 3.2.2 IQWiG GM 4.0).
According to § 35a par. 1 SGB V, the number of patients
and patient groups for which a therapeutically relevant
additional benefit exists is to be determined as part of the
benefit assessment. The extent of the additional benefit
and its therapeutic importance are quantified using de-
fined categories (§ 5 par. 7 AM-NutzenV) for each group
of patients (§ 4 par. 1 and § 5 par. 4 AM-NutzenV). The
results of subgroup analyses can help to identify these
patients or patient groups (Section 4.2.5.5 Suppl. G-BA
VerfO).
The G-BA VerfO (Section 4.2.5.5 Suppl. G-BA VerfO)
further specifies that the effect modifiers sex, age, disease
severity or disease stage as well as country and study
centre-effects should always be analysed. In addition to
these characteristics, other clinical factors related to the
treatment (e.g. dose level) should be considered. Biometric
tests to help avoid errors in interpretation of results are
proposed (e.g. homogeneity or interaction tests).
According to IQWiG, subgroup analyses of other va-
riables may, however, not always yield reliable results
and are therefore viewed with great caution (Section
7.1.6 IQWiG GM 4.0), especially if i) if they are per-
formed post-hoc, i.e. have not been planned a priori (as
part of the study protocol or protocol amendments), ii)
if numerous subgroups are analysed (multiple testing),
and, hence, false positives may arise by chance (α-error),
and iii) if the size of subgroups is small, i.e. if the power
of the statistical analyses performed is low, and false
negatives may arise by chance (β-error).
Study duration is considered an important criterion
for identifying studies that are relevant for benefit as-
sessment (Section 3.2.3 IQWiG GM 4.0). To determine
the minimum study duration, indication-specific guide-
lines from regulatory authorities or international orga-
nisation (e.g. ICH) are taken into account.
Comparator and comparison The benefit and additional
benefit of a new pharmaceutical drug are assessed by com-
parison with a specific appropriate comparator (§ 2 par.
5 AM-NutzenV). The pharmaceutical company can choose
from several comparators, which are determined by the
G-BA (§ 6 par. 2a AM-NutzenV). The following criteria
are taken into consideration: i) the comparator should beselected using methods that correspond to the inter-
national standards of evidence-based medicine (§ 6 par.
1 AM-NutzenV); ii) the comparator should be an appro-
priate therapy in the therapeutic indication according to
the generally accepted state of medical knowledge (§ 6 par.
2 AM-NutzenV); iii) the comparator should preferably be
a therapy for which there are endpoint studies and which
has proven itself in practical use, unless this is in oppo-
sition to guidelines or the efficiency principle (§ 6 par.
2 AM-NutzenV); iv) if a pharmaceutical is considered as
the comparator, the pharmaceutical must be authorised
for the therapeutic indication (Section 3.1 Suppl. G-BA
VerfO); v) if a non-medicinal treatment is considered as
the comparator, this must be deliverable within the frame-
work of the statutory health insurance (i.e. reimbursable)
(Section 3.1 Suppl. G-BA VerfO); vi) those comparators
are preferred whose patient-relevant benefit has already
been determined (i.e. pre-assessed) by G-BA (Section 3.1
Suppl. G-BA VerfO); vii) for pharmaceuticals of an active
substance class, the same appropriate comparator must be
used to guarantee a uniform assessment (§ 6 par. 3 AM-
NutzenV); viii) the comparator must also be suitable for
assessing existing pharmaceuticals (upon request from
G-BA) that were made available on the market before 1
January 2011 (Section 3.1 Suppl. G-BAVerfO).
Pharmaceutical companies can request consultation
from G-BA on the choice of appropriate comparator, on
design aspects of studies, and on the content of the docu-
ments to be submitted (§ 35a par. 7 SGB V). The consul-
tation procedure may take place before phase 3 clinical
studies or submission (§ 8 par. 1 AM-NutzenV).
While evidence from direct comparisons based on
head-to-head RCTs is generally preferred, it may not be
available or insufficient at the time of early benefit assess-
ment (Section 7.3.9 IQWiG GM 4.0). Indirect com-
parisons may then be used to determine the relative
effectiveness, provided studies are adequate for indirect
comparisons (§ 5 par. 5 AM-NutzenV). Some methodo-
logical specifications are provided in the dossier template
(Section 4.2.5.6 Suppl. G-BA VerfO). Non-adjusted in-
direct comparisons (i.e. comparisons based on studies
without a common comparator) are considered inaccep-
table. Otherwise, no clear preference is given regarding
the type of analysis used for comparing indirectly. Both
simple [15] and complex adjusted analyses can be used,
e.g. Bayesian analysis, mixed-treatment-comparison meta-
analyses [16], multiple-treatment-meta-analyses [17] or
network meta-analysis [18].
Clinical endpoints/outcomes Patient-relevant outcomes
are not only preferred, but required, as per definition of
benefit in § 2 par. 3 AM-NutzenV; in particular mortality,
morbidity (complaints and complications), and quality of
life have to be taken into account. Only if patient-relevant
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based on other data (§ 5 par. 5 AM-NutzenV). Patient-
reported outcomes such as health-related quality of life
(HRQL) and symptom scores may also be used provided
that the instruments used are validated (Section 3.2.4
IQWiG GM 4.0). As supplementary information, treat-
ment satisfaction of patients may be taken into account
(Section 3.1.1 IQWiG GM 4.0). Utilities such as quality-
adjusted life years (QALYs) may also be considered in the
assessment.
If data on patient-relevant endpoints are not available,
surrogate endpoints may be used (Section 4.5.3 Suppl.
G-BA VerfO). In general, only valid surrogate outcomes
are accepted (Section 4.5.4 Suppl. G-BA VerfO). For
validation, usually a meta-analysis is required, which
investigates the effects of an intervention on both the
surrogate outcome and the patient-relevant endpoint
of interest [19,20]. The studies included in the meta-
analysis should be conducted in patient populations and
using interventions, which are relevant to the indication,
pharmaceutical and comparator to be assessed. The use
of other alternative methods for validation e.g. [21]
should be justified, especially if they are based on only
one study. While it is accepted by IQWiG that surrogate
endpoints are especially important for early benefit
assessment, it is also emphasized that there is no vali-
dation standard, i.e. no ideal evaluation method or
criterion which would generally be accepted to support
validity of surrogate endpoints (Section 3.1.2. IQWiG
GM 4.0).
Validation should be performed within a sufficiently
defined patient population (indication) and comparable
interventions (pharmaceuticals with similar mode of
activity), which drastically limits transferability. More-
over, the correlation of the effects on the surrogate end-
point and true endpoint) should be high and biologically
or pharmacologically plausible. Above all, if the causal
relationship is not proven, changes in surrogate end-
points do not allow inferences on changes in patient-
relevant endpoints [22].
In a recent Rapid Report by IQWiG on the validity of
surrogate endpoints in oncology, data from 21 validation
studies on breast cancer and colon cancer of different
stages (early or advanced, with or without metastases)
were examined [23]. Overall survival rate was identified
as the only valid patient-relevant endpoint; no valid sur-
rogate endpoint was identified.
Surrogate outcomes of unclear validity may be ac-
cepted by IQWiG as outcomes of interventions for
extremely serious diseases with high morbidity and mor-
tality, for which there are no treatment alternatives [24].
Surrogate outcomes that have not been fully evaluated
may be used based on the concept of surrogate thresh-
old effects [25].Composite outcomes are generally also not preferred
but accepted if clinical trials reporting single outcomes are
not available. Composite outcomes are included in the
benefit assessment only if all components are patient-
relevant endpoints and also reported separately (Section
7.1.5 IQWiG GM 4.0).
In addition to the potential benefit of an intervention,
e.g. a decrease in mortality, the evaluation of potential
harm is another essential component of the assessment
(Section 3.1.3 IQWiG GM 4.0). To evaluate the benefit-
harm ratio, adverse events are to be analysed and
presented. Relevant adverse effects may partly or fully
counterbalance the benefit of the intervention, may be
considered especially important by patients, or be asso-
ciated with serious morbidity, higher mortality, or signifi-
cant impact on quality of life.
Statistical analysis and categorisation of outcome
If the available studies are suitable for meta-analysis, re-
sults from individual studies should be pooled quan-
titatively to enhance the validity and certainty of results
(Section 7.2.1, 7.2.2 and 7.3.8 IQWiG GM 4.0, and Section
4.2.5.3 Suppl. G-BA VerfO). The overall quality of syste-
matic reviews is assessed using the validated quality in-
dices from Oxman and Guyatt or the AMSTAR tool.
Potential heterogeneity of the study results is to be
assessed using the I2 measure or other statistical tests for
heterogeneity [26]. Possible reasons for heterogeneity such
as methodical and clinical aspects or effect modifiers
should be investigated. Sensitivity analyses should be con-
ducted to assess the robustness of the results if there are
differences between studies in terms of methodological as-
pects regarding the information retrieval and evaluation,
e.g. cut-off dates or selection of effect measures (Section
4.2.5.4 Suppl. G-BAVerfO).
The certainty of results for a given study depends on
quality of the evidence base and in particular three factors:
the type of study design (evidence level), the internal vali-
dity, and the size of the observed effect (Section 3.3.2
IQWiG GM 4.0). A classification system is used to
indicate the evidence level of the studies included in the
benefit assessment (§ 5 par. 6 AM-NutzenV]. Levels of
evidence are defined for systematic reviews of RCTs (I a),
RCTs (I b), systematic reviews of prospective comparative
cohort studies (II a), prospective comparative cohort stu-
dies (II b), retrospective comparative studies (III), case
series and other non-comparative studies (IV), and other
observations, opinions, or reports (V).
Internal validity at the study level is to be assessed in
terms of potential bias, i.e. the discrepancy between the
conditions of the study (planning, conduct, analysis, and
reporting) and the real-world situation (Section 4.2.4
Suppl. G-BA VerfO; Section 7.1.4 IQWiG GM 4.0). The
study findings may thus result from the actual therapeutic
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forms of bias such as selection bias, information basis, at-
trition bias, reporting bias, and publication bias (Section
7.3.11 IQWiG GM 4.0). The potential of bias is to be eval-
uated and classified as “high” or “low” for randomised
studies.
For internal validity at the endpoint level the following
aspects are to be considered: blinding of the endpoint
collector, adequate implementation of the ITT-principle,
and result-independent reporting. The potential of bias
is to be evaluated and classified as “high” or “low” for
endpoints used in randomised studies (Section 4.2.4
Suppl. G-BA VerfO; Section 7.1.4 IQWiG GM 4.0).
If studies of appropriate quality and precision are not
available, it is one of the principle tasks of IQWiG (Section
1.2.5 IQWiG GM 4.0) to describe the evidence base as such
and to draw the conclusion that the currently available evi-
dence base does not allow any reliable recommendations.
As a consequence, further evidence of the best-available
level of quality may be requested by G-BA (§ 5 par. 3 AM-
NutzenV].
Efficacy data from clinical studies are never extrapo-
lated qualitatively or quantitatively even if clinical effect-
iveness data are not available or limited [24]. For
example, if there are no long-term data, short-term data
are not extrapolated through modeling.
The generalisability, or external validity, should be
evaluated by describing whether and to what extent the
study results are transferable to local conditions (e.g. pa-
tient population, qualification of physicians) (Section
1.2.6 IQWiG GM 4.0). Studies that reflect the routine
setting of the German health care system are particularly
relevant.
As seen from the perspective of IQWiG, RCTs that
combine generalisability and high result certainty are
feasible and desirable (Section 1.2.6 IQWiG GM 4.0). In
these “pragmatic trials” [27], “real world trials” [28], or
“practical trials” [29] there are no defined study visits
and no special requirements for the patients, which
would go beyond what is necessary for treatment.
Part of the benefit assessment is to evaluate the actual
effects of interventions with the highest possible level of
result certainty. The certainty that an additional benefitTable 1 Requirements for the conclusions of early benefit ass
Requirement





1exists is affected by the quality of the evidence provided.
The probability of the additional benefit is assessed with
respect to the number of patients and the extent of the
additional benefit (§ 5 par. 4 AM-NutzenV] and is differ-
entiated by using the categories proof, indication, hint,
no proof and no indication (Section 3.1.1 IQWiG GM
4.0). The requirements for the various conclusions on
the evidence base are presented in Table 1 (Section 3.1.4
IQWiG GM 4.0).Methodological requirements for single technology
appraisal in England (NICE)
Legal basis, guidance texts, and information sources
Legal and guidance texts related to single technology
appraisal The pivotal legal text related to HTA in England
is the Directions of the Secretary of State [4], which de-
fines the purpose of the NICE, i.e. to conduct appraisals
and develop guidelines. All relevant methodological re-
quirements and procedural aspects regarding HTA are
laid down in guidance documents issued by NICE. The
methods of technology appraisal are described in the
“Guidance for Manufacturers and Sponsors. The Tech-
nology Appraisals Process Series No. 5” (GMS TAPS 5)
[5] and the “Guide to the methods of technology appraisal”
(GMTA) [30]. The methods considered by NICE to be the
most appropriate for the purpose of the appraisal are pre-
sented for a defined “reference case” (Section 5 GMTA).
Further information is found in the “Specification for
manufacturer/sponsor submission of evidence STA”
(SMSE STA) [31]. The procedure of the single technology
appraisal is described in the “Guide to the single technol-
ogy appraisal (STA) process” [32].Information sources The appraisal process relies on in-
formation and input from numerous sources, including
independent assessment groups, manufacturers, health-
care professionals, clinical specialists and patient/carer
representatives, who all act as suppliers of evidence,
commentary, and/or analysis (Section 1.1.4 GMTA). The
best-available data, which are relevant to the question
being addressed, should form the basis of the evaluation
(Section 2.1.1 GMS TAPS 5).essment in Germany
Certainty of results Effect
Mostly high In the same direction
Mostly moderate In the same direction
High Statistically significant
Mostly low In the same direction
Moderate Statistically significant
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manufacturers/marketing authorisation holders should
list all clinical and follow-up studies sponsored by them
or known to them, unpublished clinical data (raw data),
part-published data (e.g. in abstract form), confidential
data, and any evidence from disease registers (Section
3.3.2 to 3.3.8, 3.3.12, and 4.2.1 GMTA). The search
strategy used and the selection process, including the
rationale for exclusion and exclusion criteria, should be
described in detail (Section 5 SMSE STA).
The structure of the submission document follows a
question and answer format. The main text, excluding
the pages covered by the template, usually should not
exceed 100 pages (SMSE STA). No appendix with
source information (clinical study reports, etc.) is re-
quired. The “decision problem” (Section A of the dos-
sier) is to be submitted by the manufacturer in advance
of the full submission [32]. It should be developed from
the final scope issued by NICE and state the key param-
eters that the information in the evidence submission
will address, including population, intervention, com-
parator(s), outcomes, and subgroups to be considered
(Section A SMSE STA).
The Evidence Review Group, which is an indepen-
dent academic group commissioned by NICE to pre-
pare an assessment report for STAs, may perform
independent searches to validate the completeness of
the evidence submitted. During its critical review, ad-
ditional analyses may be requested from the manufac-
turer or sponsor.
Healthcare professionals from professional organisa-
tions of the appropriate clinical disciplines provide a
professional view of the technology’s effectiveness in
the context of routine clinical practice (Section 4.4.2
GMTA). This evidence supplements the information
available from published licensing studies, which exa-
mine clinical efficacy under controlled conditions.
Individual patients or carers, or groups of patients or
carers are requested to give their views, assessments
and evaluations during the appraisal (Section 4.3.1
GMTA) as this evidence is considered unique and rea-
listic expert knowledge about the personal impact of a
disease and its treatment (Section 4.3.5 GMTA). Pa-
tient experience may also identify limitations in the
existing research literature.
Moreover, selected clinical specialists and patient ex-
perts provide further written evidence and are invited
to attend and actively participate in the meeting of the
Appraisal Committee (Section 4.5.1 GMTA).
Finally, NICE may sometimes use publications by
other HTA agencies (e.g. HTA reports), clinical guide-
lines, and the European or national public assessment
reports (including the SmPC) [24]. Other sources such
as web-based study registries are not considered.Clinical study design and methodology
Study design features The key aspects regarding study
design (e.g. participant flow) and methods (e.g. statistical
analysis) of the included studies are to be described
according to the CONSORT [11] checklist (Section 5.3.1
SMSE]. Details on the search strategy used and results
of the quality assessment should be provided for both
RCTs and non-RCTs, preferably under consideration
of guidance issued by the Centre for Review and
Dissemination [33].
While data from well-conducted RCTs are generally
preferred, the focus of the appraisal is on effectiveness
rather than efficacy, and RCTs may thus be considered
not appropriate in some situations (Section 2.1.2 GMS
TAPS 5; Section 3.3.2 GMTA). More specifically, licen-
sing RCTs may often be too short in duration, restricted
to highly defined patient groups, and use comparator
therapies that are not routinely used in national health
care practice (Section 3.3.3 GMTA).
Ideally, data should be collected from randomised,
controlled, prospective studies with a “naturalistic de-
sign” and conducted in a routine care setting (Section
2.1.3 GMS TAPS 5). Studies in a natural and country-
specific setting (“community effectiveness”), however, are
not available in most cases.
If possible, data from RCTs should be supplemented
by good-quality data from experimental or observational
non-RCTs or other sources (Section 3.3.5 GMTA). Data
should be adjusted by using modeling to evaluate im-
portant aspects regarding comparative clinical (and cost)
effectiveness such as long-term therapeutic outcome.
As part of the scope, NICE defines the patient popula-
tion (e.g. age, sex, co-morbidities) and, if appropriate,
subpopulations of interest, and the treatment setting
(inpatient; outpatient) (Section 2.2.3 GMTA). Since one
of the aims of the appraisal is to identify those patients
most likely to benefit from treatment, subgroup analyses
are generally to be carried out. The choice of subgroups
(e.g. ‘high-risk’ patients) are to be determined a priori
and to be supported by a biological rationale, clinical
plausibility, social aspects, or other justified factors
(Section 5.10 GMTA). The analysis is to be done only
for the primary outcome, be complemented by statistical
tests of interaction, and be corrected for multiple com-
parisons (Section 2.8.4 GMS TAPS 5).
The time span to be covered in the appraisal normally
equates to the period during which the main differences
in therapeutic effects (and use of resources) are expected
to be observed; thus a lifetime horizon should be chosen,
for example, if between-treatment differences in survival
rate are to be reflected (Section 5.1.15 to 5.1.17GMTA).
Usually, modeling is required to extrapolate data from
the available evidence and to give more suitable esti-
mates for benefit parameters (Section 5.7 GMTA).
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which comprises contributions from manufacturers and
sponsors and other stakeholders (e.g. patients, carers,
clinical experts), NICE determines which comparators
are relevant for the appraisal (Section 2.4.1 GMS TAPS 5).
The main comparators are typically the interventions
most commonly used in the NHS for the patient group
of interest (Section 2.5 GMS TAPS 5). If there is another
technology that is more cost-effective than the most fre-
quently used technology, this should also be considered
as comparator in addition to best standard care (Section
5.1.7 and 6.2.2 GMTA; Section 2.5 GMS TAPS 5). Thus,
there will be often more than one relevant comparator.
The choice of comparator is not limited to (branded or
generic) pharmaceuticals but may also include non-
pharmaceutical interventions (e.g. surgical procedures)
(Section 2.2.5 GMTA). Finally, the comparator may also
be palliative therapy, no therapy, or a non-licensed
intervention if it is routinely used in clinical practice
(Section 6.2.4 GMTA) [24].
Direct ‘head-to-head’ comparisons of RCTs are clearly
preferred, provided the outcome measures and patient
groups are relevant (Section 2.2.8, 3.3.2 to 3.3.3, and
5.2.12 GMTA). If licensing studies were controlled with
placebo or a comparator not relevant to standard care in
England, modeling may be used to indirectly compare
study arms from separate studies with a common com-
parator (Section 2.5 GMS TAPS 5). When performing
indirect comparison or mixed treatment comparisons a
rationale for identifying and selecting studies should be
presented together with an assessment of quality and
heterogeneity (Section 5.2.12 to 5.2.18 GMTA; Section
5.7.2 SMSE STA).
Clinical endpoints/outcomes Endpoints that are to be
included in the assessment are identified during the
scoping. Outcome measures can be either final (clinical)
endpoints or intermediate (surrogate) endpoints. During
the appraisal of an intervention all the clinical benefits
and costs are evaluated “in the broadest sense” (Section
1 GMS TAPS 5). Clinical outcome data should allow
evaluation of long-term clinical effectiveness by mea-
suring the impact on morbidity, mortality, and HRQL.
Changes in HRQL (e.g. pain relief ) should preferably be
reported directly from patients, using a standardised in-
strument such as EQ-5D, if possible. Data on mortality
and quality of life should not only be presented sepa-
rately but also be combined in form of QALYs. In this
way, i.e. by calculating utility measures, cost effective-
ness can be evaluated (Section 2.6 and 2.12.2 GMS
TAPS 5; Section 5.3 GMTA).
In any case, outcome measures should be relevant to
patients and/or carers (Section 2.2.8 GMTA). Patients
ideally should themselves assess their status of health ateach disease stage (Section 2.6 GMS TAPS 5). Treat-
ment compliance may also be measured (Section 5.3.5
SMSE STA). Ease of use of the technology (patient
friendliness) is considered to be included in the HRQL
[24]. Finally, experience with the use of the technology is
considered relevant if experience is known to affect the
efficacy or effectiveness, as in surgical procedures for
example [24].
Intermediate (surrogate) outcomes may be included in
the assessment if either a strong and consistent correlation
between the intermediate outcome and final outcome can
be shown or if the outcome measured is large, precise and
lasting (Section 2.1.4 GMS TAPS 5). For early appraisals
of new technologies modeling using data from interme-
diate outcomes is acceptable when long-term outcome
data are not available. Validation may be postponed until
epidemiological data have been collected (Section 2.1.5
GMS TAPS 5). Composite endpoints are included in the
assessment [24].
Safety data from comparative RCTs, non-comparative
RCTs (e.g. post-marketing pharmacovigilance data) and
regulatory summaries are considered in the relative ef-
fectiveness assessment (Section 5.9 SMSE STA). Adverse
events reported on treatment with the new technology
as compared with the comparator compound are to be
identified using a defined search strategy and subjected
to a quality assessment.
Statistical analysis and categorisation of outcome
To enhance the evidence base regarding clinical effec-
tiveness, manufacturers and sponsors of product are ad-
vised to carry out an up-to-date systematic review which
includes data from published and unpublished trials in
the relevant patient population. In addition, NICE may
itself also commission an independent review (Section
2.8.5 GMS TAPS 5).
Systematic reviews should be conducted according to
a previously prepared protocol and based on studies
with least potential of bias (Section 4.2.3, 5.2.2, 5.2.4 and
6.2.6 GMTA). Eligible studies must be assessed using ap-
propriate inclusion and exclusion criteria (Section 5.2.5
GMTA). Before further data analysis, potential treatment
effect modifiers such as patient characteristics (e.g. age,
sex, severity of disease), care setting, and year of the
study should be identified (Section 5.2.7 GMTA).
Data should be pooled and explored further by meta-
analysis if the quality of data is adequate (Section 5.2.8
GMTA). The characteristics and limitations should be
described for each study in terms of population, inter-
vention, setting, sample size, and validity (Section 5.2.9
GMTA). The degree of heterogeneity, i.e. any variability
in addition to that accounted for by chance, and reasons
for it should be investigated as far as possible (Section
5.2.10 GMTA).
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and limitations associated with the analyses of clinical
effectiveness should be evaluated using sensitivity ana-
lyses (Section 5.2.10 and 5.8.4 GMTA). Potential bias
and uncertainty may result from selective use of informa-
tion, parameter precision, and structural assumptions
underlying a model. Therefore, sensitivity analyses should
be performed to critically evaluate the effects of incorpor-
ating or excluding parts of the information supplied as
evidence for the appraisal (e.g. a specific study) (Section
5.2.10, 5.8.4 to 5.8.6 GMTA); probabilistic sensitivity ana-
lysis should be performed to characterise uncertainty asso-
ciated with parameter precision, i.e. distribution around
the mean parameter values (Section 5.8.7 5.8.4 GMTA);
and sensitivity analyses should be performed to test alterna-
tive choices of time span, key parameter, or other methodo-
logical aspects (e.g. classification of disease stages; choice
of treatment modalities) when using modeling techniques
(Section 5.7.1, 5.7.7 and 5.8.5 GMTA).
A classification system is used to indicate the level of
evidence of the included studies. The best-quality evidence
can be obtained from experimental studies (RCTs) with
high internal and external validity (Section 3.3.2 to 3.3.3
GMTA). Lower validity, i.e. greater potential for bias with
regard to performance, measurement and attrition, is found
in uncontrolled observational studies (Section 3.3.4 to 3.3.5
GMTA). In any case, the value of the available evidence
also depends on its relevance for the appraisal to the ques-
tion defined in the scope.
The uncertainty and limitations associated with the evi-
dence available should be clearly presented (Section 3.2.2
GMTA). To this end, the quality of a study (internal
validity) should be assessed on the basis of study design
characteristics and aspects related to study conduct
(Section 3.3.3 GMTA; Section 5.4.1 SMSE STA). Potential
bias, which may lead to a systematic deviation of the
effects estimated from study data from the true effect,
may be introduced by the method of blinding, method
of randomisation, concealment of allocation, duration
of follow-up, similarity of groups at baseline, overall size
of study population (and imbalances in drop-out rates),
selection, measurement, and reporting of outcomes,
and data analysis (intention-to-treat analysis; handling
of missing data). Potential bias and uncertainty, which
may result from the selective use of information from
studies and estimates of clinical effectiveness, should
be quantified as far as possible (Section 5.2.3 and 5.8.5
to 5.8.6 GMTA).
Rapid evaluations for new interventions are often con-
ducted based on data from licensing studies before long-
term clinical data of best quality are available. At the
same time, the technology appraisal should reflect the
time period during which the main effects on health and
use of health care resources are expected or observed(Section 5.1.15 and 5.7.7 GMTA). In this situation, ex-
trapolation (or modeling) is considered appropriate to
make best use of the existing data to allow for a thor-
ough assessment (Section 2.7 GMS TAPS 5). Modeling
may also be required if the patient population, clinical
settings, choice of comparator, type of outcomes are not
directly relevant for the appraisal decision (Section 5.7.2
and 5.7.5 GMTA; Section 2.7 GMS TAPS 5). In general,
qualitative description of generalisability or quantitative
extrapolation (modeling) should be used to transform
efficacy data, as far as possible, to effectiveness data, i.e.
to adjust data from controlled trials to what would be
expected in clinical practice. Currently accepted best
practices should be used e.g. [34,35] and all metho-
dological aspects, including the model structure, any
assumptions made, and data sources should be clearly pre-
sented and scientifically justified (Section 5.8.2 GMTA).
Concluding the appraisal, NICE classifies its decision
or recommendation regarding clinical effectiveness into
one of four categories [36]: recommended; optimised
(i.e. recommended for a specific subgroup of patients;
only in research (e.g. in the context of a clinical trial);
not recommended.
Discussion
The guidelines that describe the methods used for the
comparative benefit assessment in Germany and England
are generally quite comprehensive. All documents are
publicly available; the current IQWiG Methods paper 4.0
is available both in German and English (Table 2).
The main source of information for the appraisal in
both countries is a dossier that is prepared by the manu-
facturer. The specifications for the dossier to be submitted
to G-BA in Germany are very detailed, comprehensive
and to be followed strictly. By contrast, the submission of
evidence by manufacturers and sponsors for appraisal of
single technologies in England is less structured and de-
tailed and allows for some flexibility.
While a few other information sources are used similarly,
there is some divergence between the two HTA systems
regarding the use of web-based study registers, confidential
data, clinical guidelines, and regulatory European or na-
tional assessment reports. NICE requests written and oral
input from patients, carers, and health care professionals,
clinical specialists and patient experts from the start
(scoping) up to the Appraisal Committee meeting, which
highlights the emphasis on the perspective of these groups.
In Germany, medical experts, patients and patient orga-
nisations are approached in writing by IQWiG before its
3-month dossier review. Medical experts, patient organisa-
tions, pharmaceutical companies, industry organisations,
pharmacists’ associations, and umbrella organisations of
medical professionals can comment on IQWIG's assess-
ment in writing and orally. Moreover, the Subcommittee
Table 2 Guidance texts and information sources for early benefit assessment in Germany (G-BA/IQWIG) and single
technology appraisal in England (NICE) – a comparison
Methodological element Benefit assessment in Germany (G-BA/IQWIG) Single technology appraisal in England (NICE)
Guidance on methodology Comprehensive, very detailed, and available publicly and
partly in English.
Comprehensive, detailed, and publicly available.
Information sources used
Dossier from manufacturer > 300 pages, plus usually > 10,000 additional pages in
confidential Module 5.
< 100 pages (no additional appendix); section on
“decision problem” to be submitted in advance.
Providers of other evidence
and/or input
Written and oral comments from medical experts, patient
organisations, pharmaceutical companies, industry organisations,
pharmacists’ associations, and umbrella organisations of medical
professionals on IQWiG’s assessment.
Evidence and input from assessment groups,
manufacturers, patients, carers, and health care
professionals throughout the appraisal.
Studies All (licensing and other) studies. All (licensing and other) studies.
Publications Literature search. Literature search (& independent search).
Data Published and confidential. Published, unpublished, and confidential.
Others HTA reports (rarely) and web-based study registries. HTA reports, public assessment reports, and
clinical guidelines.
Abbreviation: G-BA Federal Joint Committee, HTA Health technology appraisal, IQWiG Institute for Quality and Efficiency in Health Care, NICE National Institute for
Health and Care Excellence.
Table 3 Clinical study design and methodology for early benefit assessment in Germany (G-BA/IQWIG) and single
technology appraisal in England (NICE) – a comparison
Methodological
element
Benefit assessment in Germany (G-BA/IQWIG) Single Technology Appraisal in England (NICE)
Study design features
Description According to international standards. According to international standards.
Study type RCTs clearly preferred; case-series acceptable if
dramatic therapeutic effect.
RCTs preferred; non-RCTs and other evidence also desired
(adjustment of data through modeling).
Subgroup analysis Always done (effect modifier; interaction tests). Always done (statistical tests).
Study duration Important criterion for relevance of evidence
(guidelines).
Data extrapolation through modeling.
Comparator and
comparison
Choice of comparator Preferably found beneficial in previous assessments;
most economic (if alternatives); preferably reference
priced; licensed; can be non-drug intervention;
consultation procedure request (advice from G-BA);
the comparator is determined by G-BA; often more
than one comparator.
Best standard care (most commonly used, most cost-effective,
also non-licensed or no intervention); input from manufacturer




Direct comparison preferred; indirect comparison
possible.
Direct comparison preferred; Indirect comparison possible.
Endpoints/outcomes
Clinical endpoints Relevance to patients (mortality, morbidity, quality of life);
reporting by patients (e.g. HRQL, symptom scores).
Relevance to patients (mortality, morbidity, quality of life) or
carers; reporting by patients (e.g. HRQL); translatable into
utilities (e.g. QALYs); ease of use of the technology;
experience with use of the technology.
Surrogate endpoints Validation study applicable to the disease, its severity,
the intervention, and the comparator required (exception:
very serious diseases).
Accepted if correlation with final endpoint is strong or
outcome measures are large.
Composite endpoints Accepted if components patient-relevant and also
reported separately.
Accepted.
Safety Analysis of relevant adverse events. Analysis of relevant adverse effects.
Abbreviation: G-BA Federal Joint Committee, HRQL Health-related quality of life; IQWiG Institute for Quality and Efficiency in Health Care, ITT intention-to-treat,
NICE National Institute for Health and Care Excellence, QALY quality-adjusted life year, RCT randomised controlled trial.
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benefit and cost-benefit assessment, also comprises mem-
bers from patient organisations.
Both HTA institutions consider study design features
(study type, (sub)population(s), and duration) to be critical
for the level, quality and relevance of the evidence base
(Table 3). While similarities prevail, NICE appears to
prefer that any kind of additional “soft” evidence be
presented if it is expected to be of relevance from the
patient/carer perspective. If possible, data should be ad-
justed or extrapolated via modeling to extract useful infor-
mation from studies of lower level (e.g. from non-RCTs)
or relevance (e.g. from too short studies). It remains to be
seen whether G-BA decisions with the condition to con-
duct additional studies will be the exception or the rule
and what kind of additional studies will be required in
which situations.
The decision of G-BA and NICE on the comparator
may be revised if the context of health care provision
changes and medical progress advances. If a new pharma-
ceutical shows a significant additional benefit, it may be-
come a future comparator in that indication. Complexity
further increases in therapeutic indications like oncology:
Different comparators will have to be selected for each
specific type of tumour (e.g. breast, lung, prostrate, colon
cancer), disease severity (early vs. advanced stage), and
treatment modality (mono vs. combination therapy).
By contrast, for technology appraisal in England, non-
licensed or no interventions are also accepted, andTable 4 Statistical analysis and categorisation of outcome for
single technology appraisal in England (NICE) – a comparison
Methodological element Benefit assessment in Germany (G-BA
Systematic reviews &
meta-analyses
Assessment of review quality; assessm
heterogeneity.
Sensitivity analyses Done with regard to methodological a
information retrieval and evaluation.
Quality of evidence base
Level of evidence Clearly defined levels of evidence.
Quality of studies (internal validity) Classification of potential bias.
G-BA may request further evidence as
the decision.





Generalisability of study results
(external validity)
Descriptive evaluation.
Categorisation of outcome Proof/indication/hint/no proof of (lack
(additional) benefit (or harm).
Abbreviation: G-BA Federal Joint Committee, IQWiG Institute for Quality and Efficienc
Care Excellence.manufacturers have the opportunity to contribute to the
choice of comparator during the early scoping process
and when submitting the draft “decision problem” in ad-
vance of the full submission. In Germany, it is possible
and generally advisable for the pharmaceutical companies
to seek advice from G-BA on the choice of the appropriate
comparator before preparing the dossier or even when
planning the pivotal phase 3 studies.
For both G-BA/IQWiG and NICE the preferred out-
comes are patient-relevant and related to mortality,
morbidity and/or quality of life. For HTA in England, out-
comes should, in addition, be translatable into utilities
(e.g. QALYs). Ease of use of the technology (i.e. patient
friendliness) and experience with the use of the technol-
ogy (e.g. prescribing rate of the pharmaceutical) are also
included as endpoints relevant to the patient and carer
perspective.
Surrogate outcomes are generally not favoured and are
considered less relevant for the final decision than clinical
outcomes. Usually, they are accepted by G-BA/IQWiG
only if they have been validated using a meta-analysis
(based on several independent RCTs) and a direct causal
relationship with the final outcome is proven. It is likely
that the cost and time required to fully confirm the scien-
tific validity of a surrogate endpoint exceeds the effort
required to conduct a single mega-trial that includes
the clinically relevant “hard” endpoint. Nevertheless, ac-
cording to current guidance in Germany, surrogate out-
comes of unclear validity are accepted only exceptionally,early benefit assessment in Germany (G-BA/IQWIG) and
/IQWIG) Single Technology Appraisal in England (NICE)
ent of Assessment of data quality; assessment of heterogeneity.
NICE may commission an additional independent review.
spects of Done with regard to methodological aspects of information
retrieval and evaluation, and uncertainty associated with
parameter precision (probabilistic sensitivity analysis).
Defined levels of evidence.
Quantification of potential bias.
part of NICE guidance may be reviewed/up-dated 1–5 years after
initial appraisal.
Quantification of potential bias
(blinding, ITT, reporting).
Qualitative extrapolation and quantitative modeling of data
regarding study duration, patient population, choice of
comparator, and type of outcomes.
Qualitative description or quantitative extrapolation
(modeling).
of) Recommended/optimised/only in research/not
recommended.
y in Health Care, ITT Intention-to-treat, NICE National Institute for Health and
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tive therapeutic options exist. By contrast, data from inter-
mediate outcomes are acceptable to NICE for early
appraisals of new technologies when long-term data are
not available. Appropriate modeling should be used and
validated when epidemiological data have been collected
over time.
As another major difference between the two HTA sys-
tems, efficacy data are never extrapolated for benefit
assessment in Germany if data on clinical effectiveness are
limited or absent (Table 4). In England, however, both
qualitative and quantitative extrapolation is performed to
adjust data if the study duration, patient population,
choice of comparator, or type of outcomes is not directly
relevant for the appraisal decision. Modeling techniques
are routinely applied to gain information on clinical ef-
fectiveness (e.g. if long-term data are absent), as part of
the cost-effectiveness analysis, and to evaluate the gene-
ralizability of study results (external validity).
Some of the discrepancies in terms of methodological
requirements between the two HTA systems may, at least
in part, be explained by differences in procedural aspects
and differences in the robustness of the data assessed at
distinct stages of the technology’s life cycle. The STA
process is initiated very early, often several months before
marketing authorisation has been granted. Thus, the
manufacturer submission of evidence may be received and
fully reviewed by the Evidence Review Group even before
a CHMP positive opinion is issued [32]. By contrast, the
dossier is submitted at market entry in Germany.
At the same time, the different purpose of the assess-
ment process may also explain differences in methodo-
logical requirements (e.g. use of modeling). While NICE
makes a recommendation regarding reimbursement based
on the (combined) appraisal of clinical and cost-effective-
ness, G-BA/IQWiG quantify the additional benefit and
its results certainty (e.g. proof, indication, or hint of ad-
ditional benefit). This information will be used, in a
second step, to support the price negotiations between the
pharmaceutical company and the statutory health insu-
rances (Figure 1).
Finally, in England, any recommendation or guidance
issued by NICE will automatically be considered for re-
view or update 1 to 5 years after the initial appraisal. The
exact review date depends on the rate at which evidence
for the technology is expected to develop, and on the
planned reporting of pivotal studies that are underway
[32]. In Germany, there is no automatic re-review of the
assessment outcome. G-BA may issue a resolution for the
initial benefit appraisal with a time restriction, however
(§ 1 par. 2 G-BA VerfO). Moreover, at the earliest 1 year
after the initial assessment, G-BA may initiate a new bene-
fit assessment because of new scientific findings; likewise,
manufacturers may request a re-assessment. In this way,the conclusions reached at the time of initial benefit as-
sessment can be revised, if deemed necessary, when new,
relevant evidence emerges.
Conclusions
The results indicate that there is some degree of similarity
regarding basic methodological elements such as selection
of information sources, quality assessment of available evi-
dence, choice of clinical endpoints, and choice of compara-
tor(s). In comparison with G-BA/IQWiG, however, NICE
appears to generally assume a less restrictive position: Sur-
rogate endpoints may be accepted more readily - provided
they are reasonably likely to predict clinical benefit - since
full validation may be postponed. Modeling is not accep-
table for benefit assessment in Germany but is expected to
be performed for HTA in England wherever possible and
appropriate, e.g. for study design features such as study
duration, patient population, choice of comparator, and
type of outcomes. There is also a greater focus on the pa-
tient and carer perspective, as evidenced by both metho-
dological elements (outcomes) and process-related aspects
(input during scoping and throughout the appraisal).
Somewhat greater flexibility is offered by requesting the
view from the manufacturer regarding the choice of com-
parator early on in the process, i.e. during the scoping and
preparation of the decision problem.
Overall, the approach taken by NICE seems to make use
of best available evidence, including data from non-RCTs.
The data are transformed using modeling techniques and
the resulting uncertainty is quantified through sensitivity
analyses before making a recommendation regarding
reimbursement. This contrasts with a more conservative
approach taken by G-BA/IQWiG, which bases its assess-
ment of the additional benefit largely, if not exclusively,
on evidence of the highest level and quality as well as data
on “hard” clinical endpoints. While NICE undertakes
a combined appraisal of clinical and cost-effectiveness
G-BA/IQWiG does not assess cost-effectiveness at the early
stage of benefit assessment. This may explain some of the
differences found, e.g. with respect to the use of modeling.
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